Refine by
Cardiac Monitoring Articles & Analysis
32 news found
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. ...
James brings 20 years of extensive experience in sales and business development roles specifically in the cardiac monitoring space in the USA. At Medicalgorithmics, he will be responsible for strengthening client relationships, expanding distribution channels, and developing sales growth initiatives for the North American market, particularly in the United ...
Bodyport’s biomarker platform is able to provide advanced cardiac monitoring and connected care to patients to support the prevention and management of heart disease. ...
The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services. Saturday, Nov. 5 3:00 – 4:00 p.m. ...
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
Cardiac arrhythmias affect not only adults, but unfortunately also children struggle with such health problems. ...
“The comprehensive health assessment from the Cardiac Scale provides metric-driven, personalized care to those in need. ...
Cardiac monitoring is especially helpful in those living with advanced heart disease, such as heart failure. ...
iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and ...
Specifically, the study demonstrated that young men in the advanced stages of DMD experienced improvements in both skeletal and cardiac muscle function after receiving four doses of CAP-1002 over the course of one year. ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The Company believes that its wireless, ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients published in the Journal of Cardiac Failure. The results of the study show that Daxor’s BVA-100 provides unique and actionable data that is ...
Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients. ...
Cardiac Failure: Monitor for signs or symptoms of cardiac failure throughout treatment with FOTIVDA. Cardiac Ischemia and Arterial Thromboembolic Events: Closely monitor patients who are at increased risk for these events. ...
Cardiac Failure: Monitor for signs or symptoms of cardiac failure throughout treatment with FOTIVDA. Cardiac Ischemia and Arterial Thromboembolic Events: Closely monitor patients who are at increased risk for these events. ...
It has been shown to provide reliable early cardiac arrest prediction which can enable medical practitioners to mount a rapid and effective response. ...
During development of the trial design, Cardiac Dimensions analyzed an extensive amount of data from more than 250 study patients previously enrolled in over four similar trials. Based on these analyses, the device safety profile, and the company’s recent publications, the trial will focus on this extremely large patient population with limited other therapeutic ...
An analysis of 48,570 cardiac cycles revealed that monitoring stroke volume change via carotid Doppler might support the diagnosis and management of evolving hypovolemia Flosonics Medical recently announced a study published in the British Journal of Anaesthesia in which Dr. ...
Russian regulatory certification for USCOM 1A Cardiac Output Monitor, Russia a significant and growing European market, Uscom continues global expansion. ...